Noopur Raje

Boston Medical Center — United States

Medicine · Health Sciences

102h-index43.7kcitations1.0kworks3.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(719), Protein Degradation and Inhibitors(251), CAR-T cell therapy research(151), Peptidase Inhibition and Analysis(146), Bone health and treatments(108)

Publications1.0k total

Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T
Leukemia·2025Open Access
Choosing the optimal maintenance strategy in multiple myeloma
Hematology·2025Open Access
Table S4 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
2025Open Access
Figure S1 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
2025Open Access
Figure S2 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
2025Open Access
In Vivo postnatal loss of mature osteoblasts creates an immunosuppressive bone marrow microenvironment to permit the engraftment and proliferation of myeloma cells
Blood·2025Open Access
Validation and refinement of the new high-risk multiple myeloma (HRMM) criteria in relapsed or refractory patients treated with BCMA CAR-T.
Blood·2025Open Access
Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study
Blood·2025Open Access
Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma
Blood·2025
Deciphering the role of EP300 in maintaining the enhancer landscape and lineage-specific epigenetic vulnerability in multiple myeloma
Blood·2025
First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance
Blood·2025Open Access
The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma
Blood·2025
Immune aging and macrophage inhibitory factor (MIF) – mediated stromal rewiring drives pre-malignant evolution in smoldering multiple myeloma
Blood·2025Open Access
Risk score and survival outcomes for multiple myeloma patients with disease refractory to BCMA CAR-T.
Blood·2025
The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial
Blood·2025Open Access
Deepening responses and MRD-conversion in a phase II fixed-duration consolidation trial of elranatamab post-idecabtagene vicleucel CAR-T cell therapy (EPIC) in relapsed or refractory multiple myeloma
Blood·2025Open Access
Targeted deep sequencing of myeloma in a multi-institutional clinical workflow
Blood·2025Open Access
365 Single-cell transcriptional profiles of cilta-cel and ide-cel associate with response in multiple myeloma
Regular and Young Investigator Award Abstracts·2025Open Access
CLINICAL COURSE OF A PREVIOUSLY HEALTHY PATIENT WITH CHRONIC ACTIVE EBV INFECTION
Annals of Allergy Asthma & Immunology·2025
Body Composition Metrics Associated with Time to Progression in Smoldering Multiple Myeloma
Diagnostics·2025Open Access
page 1 of 52Next →

Frequent Co-authors

Kenneth C. Anderson(34), Paul G. Richardson(25), Teru Hideshima(22), Nikhil C. Munshi(21), Dharminder Chauhan(14), Shaji Kumar(10), Yu‐Tzu Tai(9), Klaus Podar(8), Sagar Lonial(7), Suzanne Lentzsch(7), Constantine S. Mitsiades(7), Philippe Moreau(6), Hartmut Goldschmidt(6), Jacob P. Laubach(6), Sonia Vallet(6), Jesús G. Berdeja(5), Michèle Cavo(5), Sundar Jagannath(5), Robert Z. Orlowski(5), Nizar J. Bahlis(5)